Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: Central cannabinoid (CB1) receptor antagonists may have potential in the treatment of a number of diseases such as neuroinflammatory disorders, cognitive disorders, septic shock, obesity, psychosis, addiction, and gastrointestinal disorders. (R)-SLV 319 is the inactive enantiomer of SLV 319 with 100-fold less affinity for the CB1 receptor. SLV 319 is a potent and selective CB1 receptor antagonist with Ki values of 7.8 and 7,943 nM for CB1 and peripheral cannabinoid (CB2) receptors, respectively. SLV 319 is less lipophilic (log P = 5.1) and therefore more water soluble than other known CB1 receptor ligands.
(R)-SLV 319 is supplied as a crystalline solid. A stock solution may be made by dissolving the (R)-SLV 319 in an organic solvent purged with an inert gas. (R)-SLV 319 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of (R)-SLV 319 in these solvents is approximately 30 mg/ml. (R)-SLV 319 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, (R)-SLV 319 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. (R)-SLV 319 has a solubility of approximately 0.25 mg/ml in a 1:2 solution of ethanol:PBS (pH 7.2) using this method.We do not recommend storing the aqueous solution for more than one day.
Lange, J.H.M., Coolen, H.K.A.C., van Stuivenberg, H.H., et al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists. J. Med. Chem. 47(3), 627-643 (2004).
Lange, J.H.M., van Stuivenberg, H.H., Veerman, W., et al. Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. Biooganic & Medicinal Chemistry Letters 15, 4794-4798 (2005).